Dose Intensity/Body Surface Area Ratio is a Novel Marker Useful for Predicting Response to Lenvatinib against Hepatocellular Carcinoma
Lenvatinib was recently approved as a novel first-line molecular targeted agent (MTA) for treating hepatocellular carcinoma (HCC). The importance of relative dose intensity (RDI) has been shown in the treatment of various types of cancers. However, RDI may not accurately reflect the treatment intens...
Main Authors: | Yuji Eso, Shigeharu Nakano, Masako Mishima, Soichi Arasawa, Eriko Iguchi, Fumiyasu Nakamura, Haruhiko Takeda, Atsushi Takai, Ken Takahashi, Kojiro Taura, Hiroshi Seno |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-12-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/1/49 |
Similar Items
-
Response to Lenvatinib Is Associated with Optimal RelativeDose Intensity in Hepatocellular Carcinoma: Experience in Clinical Settings
by: Ryu Sasaki, et al.
Published: (2019-11-01) -
The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study
by: Kaoru Tsuchiya, et al.
Published: (2021-05-01) -
Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study
by: Kazuomi Ueshima, et al.
Published: (2019-07-01) -
Health‐related quality‐of‐life analyses from a multicenter, randomized, double‐blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day
by: Matthew H. Taylor, et al.
Published: (2023-02-01) -
Comparing the impact of atezolizumab plus bevacizumab and lenvatinib on the liver function in hepatocellular carcinoma patients: A mixed‐effects regression model approach
by: Takeshi Hatanaka, et al.
Published: (2023-12-01)